Hideki Kakeya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hideki Kakeya has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Garimagai Borjigin
Research Fellow of Japan Society for the Promotion of Science
4 shared publicationsHiroto Omori
University of Tsukuba
3 shared publicationsShimpei Sawada
Department of Intelligent Interaction Technologies, University of Tsukuba, 1-1-1Tennodai, Tsukuba, Ibaraki 3058573, Japan
3 shared publications- Yoshitaka Umeno
The University of Tokyo
3 shared publications Yukari Kamijima
Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan
3 shared publications- Hiroshi Kusunoki
Department of Internal Medicine, Osaka Dental University, 8-1 Kuzuhahanazonocho, Hirakata 573-1121, Osaka, Japan
2 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Korean Society for Preventive Medicine in Journal of Preventive Medicine and Public Health
- Vol. 59 (4) , 343-351
Reassessing Early COVID-19 Strategies in East Asia: Insights From Japan and Korea
East Asian countries had remarkably low coronavirus disease 2019 (COVID-19) mortality in 2020, a pattern widely cited as evidence of effective public health interventions. However, Japan and Korea—often classified as having followed similar early intervention strategies—adopted substantially different approaches. These differences are largely obscured by commonly used stringency indices and policy score analyses. While neither country implemented a lockdown, Korea pursued an aggressive, government-mandated strategy based on extensive testing, isolation, quarantine, and compulsory data collection. In contrast, Japan relied on a voluntary model with limited mass testing, a policy that drew strong criticism during the early phase of the pandemic. Because asymptomatic COVID-19 infection was highly prevalent, these divergent testing policies were particularly important in shaping patterns of community transmission. Using excess mortality as a comprehensive outcome metric, Japan’s outcomes were as favorable as Korea’s through the pre-Omicron period, despite Japan’s limited testing. In 2020, excess mortality was negligible in both countries (−1.7% in Japan vs. +0.3 to +2.1% in Korea). In 2021, excess mortality increased modestly (+2.2% vs. +4.0 to +5.6%). However, in 2022, despite approximately 80% vaccination coverage in both countries, excess mortality reached +7.6% in Japan and about +20% in Korea—three times the Japanese level despite Korea’s much higher booster rate. These patterns of excess mortality in 2 countries with contrasting testing strategies challenge the view that East Asia’s early success stemmed primarily from stringent virus suppression measures. They highlight the need to consider alternative explanations, including the possibility that pre-existing immunity differed substantially across geographical regions.
- 31 July 2026
- Published by Korean Society for Preventive Medicine in Journal of Preventive Medicine and Public Health
- Vol. 59 (4) , 343-351
Open AccessReassessing Early COVID-19 Strategies in East Asia: Insights From Japan and Korea
East Asian countries had remarkably low coronavirus disease 2019 (COVID-19) mortality in 2020, a pattern widely cited as evidence of effective public health interventions. However, Japan and Korea—often classified as having followed similar early intervention strategies—adopted substantially different approaches. These differences are largely obscured by commonly used stringency indices and policy score analyses. While neither country implemented a lockdown, Korea pursued an aggressive, government-mandated strategy based on extensive testing, isolation, quarantine, and compulsory data collection. In contrast, Japan relied on a voluntary model with limited mass testing, a policy that drew strong criticism during the early phase of the pandemic. Because asymptomatic COVID-19 infection was highly prevalent, these divergent testing policies were particularly important in shaping patterns of community transmission. Using excess mortality as a comprehensive outcome metric, Japan’s outcomes were as favorable as Korea’s through the pre-Omicron period, despite Japan’s limited testing. In 2020, excess mortality was negligible in both countries (−1.7% in Japan vs. +0.3 to +2.1% in Korea). In 2021, excess mortality increased modestly (+2.2% vs. +4.0 to +5.6%). However, in 2022, despite approximately 80% vaccination coverage in both countries, excess mortality reached +7.6% in Japan and about +20% in Korea—three times the Japanese level despite Korea’s much higher booster rate. These patterns of excess mortality in 2 countries with contrasting testing strategies challenge the view that East Asia’s early success stemmed primarily from stringent virus suppression measures. They highlight the need to consider alternative explanations, including the possibility that pre-existing immunity differed substantially across geographical regions.
- Open Access
- 11 July 2026
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 143, 105989
Unusual enrichment of rare C-to-G transversions in the SARS-CoV-2 delta spike
- 11 July 2026
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 143, 105989
Open AccessUnusual enrichment of rare C-to-G transversions in the SARS-CoV-2 delta spike
- Open Access
- 25 June 2026
- Published by Springer Nature in Research Square
All-cause mortality patterns according to vaccination timing and dose number among Japanese non-elderly adults: a proxy risk-group analysis
Background Interpretation of mortality differences across COVID-19 vaccine dose groups is complicated by confounding by indication and healthy vaccinee bias. We examined all-cause mortality among non-elderly individuals according to both the timing and number of COVID-19 booster doses. Methods Using vaccination and mortality data from Matsudo City, Japan, individuals born between 1961 and 2005 were analyzed. Vaccination groups were defined by timing and number of booster doses (4th–7th doses). Mortality within 180 days and between 181–360 days after vaccination was compared across groups. Results Mortality rates increased with the number of vaccine doses. Mortality was lower in later 4th- and 5th-dose groups than in earlier-dose groups, consistent with confounding by indication. However, among individuals who did not receive a subsequent dose, mortality between 181–360 days after vaccination exceeded mortality within 180 days after the subsequent dose among those who continued vaccination. Mortality after the 6th and 7th doses was higher than after earlier booster doses among proxy high-risk individuals. Conclusions Confounding by indication was evident but did not fully explain the observed mortality patterns. Mortality rates increased with the number of doses even when the analysis is restricted to proxy high-risk groups. Further studies incorporating clinical and socioeconomic factors are warranted.
- 25 June 2026
- Published by Springer Nature in Research Square
Open AccessAll-cause mortality patterns according to vaccination timing and dose number among Japanese non-elderly adults: a proxy risk-group analysis
Background Interpretation of mortality differences across COVID-19 vaccine dose groups is complicated by confounding by indication and healthy vaccinee bias. We examined all-cause mortality among non-elderly individuals according to both the timing and number of COVID-19 booster doses. Methods Using vaccination and mortality data from Matsudo City, Japan, individuals born between 1961 and 2005 were analyzed. Vaccination groups were defined by timing and number of booster doses (4th–7th doses). Mortality within 180 days and between 181–360 days after vaccination was compared across groups. Results Mortality rates increased with the number of vaccine doses. Mortality was lower in later 4th- and 5th-dose groups than in earlier-dose groups, consistent with confounding by indication. However, among individuals who did not receive a subsequent dose, mortality between 181–360 days after vaccination exceeded mortality within 180 days after the subsequent dose among those who continued vaccination. Mortality after the 6th and 7th doses was higher than after earlier booster doses among proxy high-risk individuals. Conclusions Confounding by indication was evident but did not fully explain the observed mortality patterns. Mortality rates increased with the number of doses even when the analysis is restricted to proxy high-risk groups. Further studies incorporating clinical and socioeconomic factors are warranted.
- Open Access
- 20 April 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1795437
Age-specific patterns of all-cause mortality across COVID-19 booster dose groups in two Japanese municipalities: an exploratory analysis
Background/purpose: COVID-19 mRNA vaccines have been reported to reduce severe COVID-19 outcomes in high-risk populations. In Japan, booster vaccinations up to the seventh dose are publicly funded; however, evidence regarding the safety and potential benefits of repeated booster doses in younger adults remains limited. This exploratory observational study aimed to describe age-specific patterns of all-cause mortality according to the number of COVID-19 vaccine doses using municipal administrative registry data. Methods: Municipal registry data obtained through information disclosure requests from Hamamatsu City (2021–2024) and Matsudo City (2021–2025) were analyzed. The dataset included age group or year of birth (5-year increments), sex, date of residence, COVID-19 vaccination records (date and lot number), and date of death. Individuals aged 20–89 years were categorized into three age groups (20–49, 50–64, and 65–89 years). All-cause mortality rates were calculated per 100,000 person-years according to the number of vaccine doses. Exploratory comparisons between dose groups were conducted using Poisson tests. Because the registry dataset lacked information on comorbidities, healthcare utilization, socioeconomic status, and cause of death, multivariable adjustment and causal inference were not feasible. Results: Age-specific differences in all-cause mortality rates were observed across vaccine dose groups. Among individuals aged 65–89 years, higher numbers of vaccine doses were associated with lower all-cause mortality rates. In contrast, among those aged 20–49 years, all-cause mortality rates were higher among individuals who had received ≥5 doses than among those who had received fewer doses. Among individuals aged 50–64 years, the all-cause mortality rate was higher among those who had received six doses than among those who had received 1, 3, or 4 doses. Conclusions: This exploratory analysis identified age-specific differences in all-cause mortality across COVID-19 vaccine dose groups. However, the dataset available so far lacked important clinical covariates and information on causes of death, limiting causal interpretation. These findings highlight the need for constructing in Japan nationally linked datasets that allow adjustment for comorbidities, healthcare utilization, and other potential confounders.
- 20 April 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1795437
Open AccessAge-specific patterns of all-cause mortality across COVID-19 booster dose groups in two Japanese municipalities: an exploratory analysis
Background/purpose: COVID-19 mRNA vaccines have been reported to reduce severe COVID-19 outcomes in high-risk populations. In Japan, booster vaccinations up to the seventh dose are publicly funded; however, evidence regarding the safety and potential benefits of repeated booster doses in younger adults remains limited. This exploratory observational study aimed to describe age-specific patterns of all-cause mortality according to the number of COVID-19 vaccine doses using municipal administrative registry data. Methods: Municipal registry data obtained through information disclosure requests from Hamamatsu City (2021–2024) and Matsudo City (2021–2025) were analyzed. The dataset included age group or year of birth (5-year increments), sex, date of residence, COVID-19 vaccination records (date and lot number), and date of death. Individuals aged 20–89 years were categorized into three age groups (20–49, 50–64, and 65–89 years). All-cause mortality rates were calculated per 100,000 person-years according to the number of vaccine doses. Exploratory comparisons between dose groups were conducted using Poisson tests. Because the registry dataset lacked information on comorbidities, healthcare utilization, socioeconomic status, and cause of death, multivariable adjustment and causal inference were not feasible. Results: Age-specific differences in all-cause mortality rates were observed across vaccine dose groups. Among individuals aged 65–89 years, higher numbers of vaccine doses were associated with lower all-cause mortality rates. In contrast, among those aged 20–49 years, all-cause mortality rates were higher among individuals who had received ≥5 doses than among those who had received fewer doses. Among individuals aged 50–64 years, the all-cause mortality rate was higher among those who had received six doses than among those who had received 1, 3, or 4 doses. Conclusions: This exploratory analysis identified age-specific differences in all-cause mortality across COVID-19 vaccine dose groups. However, the dataset available so far lacked important clinical covariates and information on causes of death, limiting causal interpretation. These findings highlight the need for constructing in Japan nationally linked datasets that allow adjustment for comorbidities, healthcare utilization, and other potential confounders.
- Open Access
- 3 April 2026
- Published by MDPI AG in Preprints.org
Emergence of the SARS-CoV-2 BA.3.2 Saltation Variant with a Distinct Mutation-Spectrum Profile Compared with BA.1 and BA.2.86
Submissions of sequences consistent with SARS-CoV-2 BA.3.2, a newly observed saltation variant, have increased in GISAID since November 2025. Saltation events are often prioritized for monitoring due to extensive divergence. Using 12-category nucleotide substitution spectra and principal component analysis, we show that BA.3.2 has a mutation-spectrum profile distinct from BA.1 and BA.2.86, lacking pronounced transversion enrichment while retaining spike-focused substitution enrichment. Unlike BA.1, BA.3.2 shows no clear enrichment of basic residue-introducing substitutions in spike.
- 3 April 2026
- Published by MDPI AG in Preprints.org
Open AccessEmergence of the SARS-CoV-2 BA.3.2 Saltation Variant with a Distinct Mutation-Spectrum Profile Compared with BA.1 and BA.2.86
Submissions of sequences consistent with SARS-CoV-2 BA.3.2, a newly observed saltation variant, have increased in GISAID since November 2025. Saltation events are often prioritized for monitoring due to extensive divergence. Using 12-category nucleotide substitution spectra and principal component analysis, we show that BA.3.2 has a mutation-spectrum profile distinct from BA.1 and BA.2.86, lacking pronounced transversion enrichment while retaining spike-focused substitution enrichment. Unlike BA.1, BA.3.2 shows no clear enrichment of basic residue-introducing substitutions in spike.
- Open Access
- 20 February 2026
- Published by MDPI AG in Microbiology Research
- Vol. 17 (2) , 44
Anomalous Emergence of D614 Reverse Mutations in the Delta and Omicron BA.2 Variants
Background: The spike D614G substitution became globally dominant early in the COVID-19 pandemic, and reversion to ancestral D614 is expected to be rare once D614G is fixed. SARS-CoV-2 sequences lacking D614G detected later raise questions about the origin of these reversions. Methods: We analyzed spike protein amino-acid sequences from 22 SARS-CoV-2 Variants of Concern (VOCs) deposited in the NCBI GenBank database, screening for sequences carrying ancestral D614 and comparing their distributions across VOCs. Results: D614 reversions (reverse mutations of D614G) were not evenly distributed across VOCs but were strongly enriched in Delta (B.1.617.2) and Omicron BA.2, reaching levels statistically inconsistent with other VOCs. In both lineages, D614-containing sequences showed limited mutational diversity and pronounced geographic clustering within specific U.S. regions. Conclusions: These non-random patterns are difficult to reconcile with spontaneous reverse mutation arising and spreading through typical community transmission and are more consistent with localized reintroduction of an older genetic background. Further investigation is warranted to assess whether laboratory-associated events could be involved.
- 20 February 2026
- Published by MDPI AG in Microbiology Research
- Vol. 17 (2) , 44
Open AccessAnomalous Emergence of D614 Reverse Mutations in the Delta and Omicron BA.2 Variants
Background: The spike D614G substitution became globally dominant early in the COVID-19 pandemic, and reversion to ancestral D614 is expected to be rare once D614G is fixed. SARS-CoV-2 sequences lacking D614G detected later raise questions about the origin of these reversions. Methods: We analyzed spike protein amino-acid sequences from 22 SARS-CoV-2 Variants of Concern (VOCs) deposited in the NCBI GenBank database, screening for sequences carrying ancestral D614 and comparing their distributions across VOCs. Results: D614 reversions (reverse mutations of D614G) were not evenly distributed across VOCs but were strongly enriched in Delta (B.1.617.2) and Omicron BA.2, reaching levels statistically inconsistent with other VOCs. In both lineages, D614-containing sequences showed limited mutational diversity and pronounced geographic clustering within specific U.S. regions. Conclusions: These non-random patterns are difficult to reconcile with spontaneous reverse mutation arising and spreading through typical community transmission and are more consistent with localized reintroduction of an older genetic background. Further investigation is warranted to assess whether laboratory-associated events could be involved.
- 16 November 2025
- Published by Springer Nature
- p. 167-175
3D Displays Using Interleaved Fresnel Lenses
- Open Access
- 3 November 2025
- Published by MDPI AG in Preprints.org
COVID-19 Booster Vaccination and Increased Mortality: Detection of a Safety Signal in a Non-Elderly Population
Background/PurposeCOVID-19 mRNA vaccines have been reported to prevent severe disease in high-risk populations. In Japan, booster doses of up to the seventh dose are publicly funded; however, the safety and benefits of frequent vaccinations in younger adults remain unclear. This study analyzed all-cause mortality by age group and number of vaccine doses, focusing on associations between frequent boosters (≥5 doses) and mortality.MethodsThe resident registry and vaccination records from Hamamatsu City (2021–2024) and Matsudo City (2021–2025) were linked to analyze all-cause mortality by age and number of vaccine doses. Three age groups were examined: 20–49, 50–64, and 65–89 years. Mortality rates were calculated using person-years, and each death was attributed to the most recent vaccine dose received.ResultsOlder adults (65–89 years) receiving ≥5 doses had lower all-cause mortality, although this may partly reflect healthy vaccinee bias, as healthier individuals were more likely to continue vaccination. In contrast, younger adults (20–49 years) showed a marked increase in mortality with ≥5 doses, and those aged 50–64 exhibited elevated mortality with six doses. These patterns suggest that selective vaccination of high-risk individuals does not fully account for the observed trends. While frequent vaccination was associated with reduced mortality in older adults but increased mortality in younger adults.ConclusionsObservational data indicated age- and dose-dependent differences in all-cause mortality after COVID-19 vaccination. Although additional doses may reduce mortality in older adults, frequent boosters in younger adults may pose potential risks. The causality cannot be established, and the underlying mechanisms remain unclear. These findings emphasize the need for careful risk–benefit assessments in younger populations and underscore the importance of nationwide confounder-adjusted analyses to inform optimized booster strategies, including vaccine type, dosing intervals, and immunological factors.
- 3 November 2025
- Published by MDPI AG in Preprints.org
Open AccessCOVID-19 Booster Vaccination and Increased Mortality: Detection of a Safety Signal in a Non-Elderly Population
Background/PurposeCOVID-19 mRNA vaccines have been reported to prevent severe disease in high-risk populations. In Japan, booster doses of up to the seventh dose are publicly funded; however, the safety and benefits of frequent vaccinations in younger adults remain unclear. This study analyzed all-cause mortality by age group and number of vaccine doses, focusing on associations between frequent boosters (≥5 doses) and mortality.MethodsThe resident registry and vaccination records from Hamamatsu City (2021–2024) and Matsudo City (2021–2025) were linked to analyze all-cause mortality by age and number of vaccine doses. Three age groups were examined: 20–49, 50–64, and 65–89 years. Mortality rates were calculated using person-years, and each death was attributed to the most recent vaccine dose received.ResultsOlder adults (65–89 years) receiving ≥5 doses had lower all-cause mortality, although this may partly reflect healthy vaccinee bias, as healthier individuals were more likely to continue vaccination. In contrast, younger adults (20–49 years) showed a marked increase in mortality with ≥5 doses, and those aged 50–64 exhibited elevated mortality with six doses. These patterns suggest that selective vaccination of high-risk individuals does not fully account for the observed trends. While frequent vaccination was associated with reduced mortality in older adults but increased mortality in younger adults.ConclusionsObservational data indicated age- and dose-dependent differences in all-cause mortality after COVID-19 vaccination. Although additional doses may reduce mortality in older adults, frequent boosters in younger adults may pose potential risks. The causality cannot be established, and the underlying mechanisms remain unclear. These findings emphasize the need for careful risk–benefit assessments in younger populations and underscore the importance of nationwide confounder-adjusted analyses to inform optimized booster strategies, including vaccine type, dosing intervals, and immunological factors.
- 30 June 2025
- Published by Journal of Mathematical Epidemiology in Journal of Mathematical Epidemiology
Unreliability in Simulations of COVID-19 Cases and Deaths Based on Transmission Models
Predictions on the number of COVID-19 infections by researchers have failed repeatedly in Japan. In this review we discuss the mathematical models that led to these failures in predictions. Specifically, we focus on two papers published in October 2023, both of which simulate counterfactual COVID-19 cases and deaths using transmission models. One paper estimates that the COVID-19 cases and deaths from February 17 to November 30, 2021 in Japan would have been as many as 63.3 million and 364 thousand respectively had the vaccination not been implemented, where the 95\% confidence interval is claimed to be less than 1\% of the estimated value. It also claims that the cases and deaths could have been reduced by 54\% and 48\% respectively had the vaccination been implemented 14 days earlier. The other paper estimates that the number of cases in early 2022, in Tokyo would have been larger than the population in the age group under 49 in the absence of the vaccination program. We reexamine the results given by these papers to find that the simulation results do not explain the real-world data in Japan including prefectures with early/late vaccination schedules. The cause of the discrepancy is identified as the low reliability of model parameters that immensely affect the simulation results of case and death counts. Finally, we review a series of failed predictions on the number of infections during the COVID-19 pandemic in Japan and discuss the implications for future public health.
- 30 June 2025
- Published by Journal of Mathematical Epidemiology in Journal of Mathematical Epidemiology
Unreliability in Simulations of COVID-19 Cases and Deaths Based on Transmission Models
Predictions on the number of COVID-19 infections by researchers have failed repeatedly in Japan. In this review we discuss the mathematical models that led to these failures in predictions. Specifically, we focus on two papers published in October 2023, both of which simulate counterfactual COVID-19 cases and deaths using transmission models. One paper estimates that the COVID-19 cases and deaths from February 17 to November 30, 2021 in Japan would have been as many as 63.3 million and 364 thousand respectively had the vaccination not been implemented, where the 95\% confidence interval is claimed to be less than 1\% of the estimated value. It also claims that the cases and deaths could have been reduced by 54\% and 48\% respectively had the vaccination been implemented 14 days earlier. The other paper estimates that the number of cases in early 2022, in Tokyo would have been larger than the population in the age group under 49 in the absence of the vaccination program. We reexamine the results given by these papers to find that the simulation results do not explain the real-world data in Japan including prefectures with early/late vaccination schedules. The cause of the discrepancy is identified as the low reliability of model parameters that immensely affect the simulation results of case and death counts. Finally, we review a series of failed predictions on the number of infections during the COVID-19 pandemic in Japan and discuss the implications for future public health.